Amylyx Pharmaceuticals Inc - Asset Resilience Ratio
Amylyx Pharmaceuticals Inc (AMLX) has an Asset Resilience Ratio of 17.25% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Amylyx Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check how strategically is Amylyx Pharmaceuticals Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Amylyx Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Amylyx Pharmaceuticals Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.63 Million | 17.25% |
| Total Liquid Assets | $50.63 Million | 17.25% |
Asset Resilience Insights
- Good Liquidity Position: Amylyx Pharmaceuticals Inc maintains a healthy 17.25% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Amylyx Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Amylyx Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Livzon Pharmaceutical Group Inc
SHE:000513 |
Drug Manufacturers - Specialty & Generic | 2.93% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Canopy Growth Corp
TO:WEED |
Drug Manufacturers - Specialty & Generic | 15.73% |
|
LAVIPHARM S.A. NA EO 1
F:BXA0 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Amylyx Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Amylyx Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.15% | $90.33 Million | $332.64 Million | -24.03pp |
| 2024-12-31 | 51.18% | $99.11 Million | $193.63 Million | +12.31pp |
| 2023-12-31 | 38.88% | $201.16 Million | $517.45 Million | -33.78pp |
| 2022-12-31 | 72.66% | $284.42 Million | $391.45 Million | +29.17pp |
| 2021-12-31 | 43.49% | $45.93 Million | $105.61 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $14.10 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more